PH-797804

Name: PH-797804
Brand: Selleck Chemicals
SKU: S2726
Rating: 5 (19 reviews)

For research use only. Not for use in humans.

Catalog No.S2726

19 publications

Molecular Weight(MW): 477.3

PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.

Selleck's PH-797804 has been cited by 19 publications

Cell Metab, 2019, 29(1):141-155

PubMed: 30174305 ( click the link to review the publication )

Nat Med, 2018, 24(3):271-281

PubMed: 29400712 ( click the link to review the publication )

Cancer Cell, 2018, 33(6):1094-1110

PubMed: 29805078 ( click the link to review the publication )

Nat Commun, 2019, 10(1):448

PubMed: 30683885 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3071

PubMed: 31296856 ( click the link to review the publication )

Oncogene, 2019, 38(49):7433-7446

PubMed: 31427736 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):376

PubMed: 31092814 ( click the link to review the publication )

Nanomedicine (Lond), 2019, 14(18):2409-2422

PubMed: 31456488 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2018, 59(10):4218-4227

PubMed: 30128493 ( click the link to review the publication )

Biochemistry, 2018, 57(48):6715-6725

PubMed: 30418016 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(8):996-1002

PubMed: 28752853 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Pharmacol Res, 2016, 113(Pt A):216-227

PubMed: 27543462 ( click the link to review the publication )

J Oral Pathol Med, 2016, 45(8):605-12

PubMed: 26775638 ( click the link to review the publication )

J Biol Chem, 2015, 290(17):10791-803

PubMed: 25752609 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8539-51

PubMed: 25890501 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(7):685-94

PubMed: 24880666 ( click the link to review the publication )

EMBO Mol Med, 2014, 5(11):1759-74

PubMed: 24115572 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3145-58

PubMed: 24762669 ( click the link to review the publication )

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description

PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.

Targets

p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
26 nM	102 nM

In vitro

PH-797804 blocks LPS-induced TNF-α production and p38 kinase activity in the human monocytic U937 cell line, with comparable IC50 of 5.9 nM and 1.1 nM. PH-797804 has no inhibitory effect on either the JNK pathway (c-Jun phosphorylation) or ERK pathway (ERK phosphorylation) in U937 cells at concentrations up to 1 μM. PH-797804 inhibits RANKL- and M-CSF-induced osteoclast formation in a concentration-dependent manner, with IC50 of 3 nM in primary rat bone marrow cells. ^[1] IC50 values for PH-797804 against the following targets have been determined to be greater than 200 μM (unless specified): CDK2, ERK2, IKK1, IKK2, IKKi, MAPKAP2, MAPKAP3, MKK7 (>100 μM), MNK, MSK (>164 μM), PRAK, RSK2, and TBK1, which means the activity of PH-797804 is specific. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
human U937 cells	NF7PUGJHfW6ldHnvckBie3OjeR?=	MYnJcohq[mm2aX;uJI9nKHB\|OHHsdIhiKGurbnHz[U1l\XCnbnTlcpQhUFOSLUK3JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDVPVM4KGOnbHzzMEBKSzVyPUCuNFAyODVizszN	M2XxSFIyPjJyNkm5
human monocytes	NEjmVYlHfW6ldHnvckBie3OjeR?=	NVjaPFFISW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCqdX3hckBud26xY4n0[ZMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNvaX7keYNm\CCWTl\hcJBp[SCycn;keYN1cW:wLDDJR\|UxRTBwMECzOEDPxE1?	M1vGfVIyPjJyNkm5
human PBMC	MmjkSpVv[3Srb36gZZN{[Xl?	NYrH[Ih3SW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCqdX3hckBRSk2FIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgWG5H[WyyaHGgdoVt\WG\|ZTDwdoV1emWjdHXkJIZweiBzIHjyJIJm\m:{ZTDMVHMhfHKnYYTt[Y51KG2nYYP1doVlKGGodHXyJFE5KGi{czygTWM2OD1yLkCxOUDPxE1?	MnvsNlE3PDF{MUG=

... Click to View More Cell Line Experimental Data

In vivo

Orally dosing of PH-797804 effectively inhibits acute inflammatory responses induced by systemically administered endotoxin in both rat and cynomolgus monkeys. PH-797804 treatment for 10 days demonstrates robust anti-inflammatory activity in chronic disease models, significantly reducing both joint inflammation and associated bone loss in streptococcal cell wall-induced arthritis in rats and mouse collagen-induced arthritis. Dose-response analysis resulted in ED50 values of 0.07 mg/kg and 0.095 mg/kg in rat and cynomolgus monkeys, respectively. PH-797804 inhibits LPS-induced TNF-α, IL-6, and MK-2 activity in a dose- and concentration-dependent manner in a human endotoxin challenge model. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse P38 kinase assay: A resin capture assay method is used to determine the phosphorylation of epidermal growth factor receptor peptide (EGFRP) or GST-c-Jun by p38 kinases. Reactions mixtures contain 25 mM HEPES, pH 7.5, 10 mM magnesium acetate, ATP (at the indicated concentration), 0.05 to 0.3 μCi of [γ-³³P]ATP, 0.8 mM dithiothreitol, and either 200 μM EGFRP or 10 μM GST-c-Jun for p38α kinase reactions. The reaction is initiated by the addition of 25 nM p38α kinase to give a final volume of 50 μl. The p38αkinase reactions are incubated at 25 °C for 30 minutes. Under these conditions, the formation of product for both p38αkinase is linear with time. The reaction is stopped, and the unreacted [γ-³³P]ATP is removed by the addition of 150 μl of AG 1 × 8 ion exchange resin in 900 mM sodium formate, pH 3.0. Once thoroughly mixed, solutions are allowed to stand for 5 minutes. A 50-μl aliquot of head volume containing the phosphorylated substrate is removed from the mixture and transferred to a 96-well plate. MicroScint-40 scintillation cocktail (150 μL) is added to each well and the radioactivity quantities using a TopCount NXT microplate scintillation and luminescence counter.
Cell Research: ^[1]	- Collapse Cell lines: Rheumatoid arthritis synovial fibroblast(s) Concentrations: -- Incubation Time: -- Method: Cell viability is evaluated using the 3-(4,5-dimethylthiazol-2-yl)-) diphenyl tetrazolium bromide assay. Absorbance is measured on an ELISA plate reader with a test wavelength of 570 nm and a reference of 630 nm. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: LPS-induced chronic inflammation rat model Formulation: PH-797804 is prepared as a suspension in a vehicle consisting of 0.5% methylcellulose and 0.025% Tween 20. Dosages: 0.001-1 mg/kg Administration: Oral gavage 4 hours before LPS administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	96 mg/mL (201.13 mM)
	Ethanol	7 mg/mL (14.66 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PH-797804 SDF

Molecular Weight	477.3
Formula	C₂₂H₁₉BrF₂N₂O₃
CAS No.	586379-66-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	CNC(=O)C1=CC(=C(C)C=C1)N2C(=CC(=C(Br)C2=O)OCC3=CC=C(F)C=C3F)C

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Pan p38 MAPK Inhibitor

SB202190 (FHPI) : Pan-p38α/β inhibitor, IC50=50 nM/100 nM.
Most Potent p38 MAPK Inhibitor

Skepinone-L ^New : p38α-MAPK, IC50=5 nM.
p38 MAPK Inhibitor in Clinical Trial

VX-702 : Phase II for Rheumatoid Arthritis.
Newest p38 MAPK Inhibitor

Skepinone-L ^New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

Related p38 MAPK Products

Pexmetinib (ARRY-614) ^New

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
SB239063 ^New

SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.
Ravoxertinib (GDC-0994) ^New

GDC-0994 is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
SB203580

SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM.

Features:First reported p38 inhibitor.
Doramapimod (BIRB 796)

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with K_d of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.

Features:The first p38 MAPK inhibitor to be tested in a phase III clinical trial.
SB202190 (FHPI)

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.
Ralimetinib (LY2228820)

Ralimetinib (LY2228820) is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Losmapimod (GW856553X)

Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pK_i of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3.
VX-702

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Features:Highly selective, orally active inhibitor of p38 MAPK.
TAK-715

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

PH-797804